WCG acquisition expands services to patient recruitment

By Melissa Fassbender contact

- Last updated on GMT

ThreeWire has screened more than 2 million patients in more than 25 countries. (Image: iStock/Kritchanut)
ThreeWire has screened more than 2 million patients in more than 25 countries. (Image: iStock/Kritchanut)

Related tags: Patient recruitment, Clinical trial

WIRB-Copernicus Group (WCG) has acquired the global patient recruitment, enrollment, and retention firm, ThreeWire.

"The ThreeWire approach to providing global clinical trial patient recruitment, enrollment, retention, and research site optimization services is a natural fit with WCG​," Mark Summers, ThreeWire CEO told Outsourcing-Pharma.com.

According to the company, it combines technology with “on-the-ground resources” to help investigators recruit and conduct clinical studies.

Additionally, ThreeWire has more than 300 clinical research professionals, called “Enrollment Assistants,” who work at study sites to close resource gaps where needed.

Other on-site recruitment services include patient chart review as a step to identify study candidates and conducting community outreach to patient groups and referral physicians.

The company’s US headquarters are Minneapolis with another base in Frankfurt, Germany.

"Together, WCG and ThreeWire accelerate study start-up for sponsors and contract research organizations (CROs), improve ROI on clinical trials, and accelerate patient access to innovative medicines,​" said Summers.  

"With the growth that ThreeWire has experienced both domestically and globally, it was time to find an organization with which they could continue to have scalable and innovative growth while ensuring their mission and values were aligned​," he added.

As part of the acquisition, terms of which were not disclosed, ThreeWire will continue to operate as an independent organization.

"There is no plan to “fully absorb” ThreeWire into WCG. WCG’s plan for ThreeWire is to support them to operate independently, while providing resources to help the company as it continues to expand, with access to capital, complementary clinical and regulatory expertise, and corporate support​," Summers explained.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars